SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-016250
Filing Date
2023-05-01
Accepted
2023-05-01 16:17:36
Documents
15
Period of Report
2023-05-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20230501.htm   iXBRL 8-K 63191
2 EX-99.1 ovid-ex99_1.htm EX-99 32400
3 GRAPHIC img34400995_0.jpg GRAPHIC 19422
4 GRAPHIC img34400995_1.jpg GRAPHIC 3808
  Complete submission text file 0000950170-23-016250.txt   252944

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20230501.xsd EX-101.SCH 2463
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20230501_pre.xml EX-101.PRE 9839
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20230501_lab.xml EX-101.LAB 13360
9 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20230501_htm.xml XML 4705
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 23873925
SIC: 2834 Pharmaceutical Preparations